Cangene awarded U.K. contract to supply Vaccinia Immune Globulin

20-Sep-2005

Cangene announced that it has been awarded a contract to supply Vaccinia Immune Globulin Intravenous (Human) ("VIG") to the U.K. Department of Health. The approximately $17 million Cdn contract was awarded to Cangene by the U.K. government. Cangene expects to complete delivery by the end of its 2006 fiscal year. Acambis plc, Cangene's VIG sales agent for territories outside North America and Israel, was instrumental in securing the contract. Cangene, in conjunction with its sales agents, is also in discussions with other foreign governments regarding a supply of VIG.

VIG is a hyperimmune product to be used in treating and preventing a type of severe reaction that may be brought on by administration of the smallpox vaccine, and is considered to be an important component of smallpox vaccination programs. Hyperimmunes are highly purified specialty antibodies made from human plasma.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...